A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolamide, interferon alfa, and interleukin-2 for metastatic melanoma.

被引：0
|
作者：
Ron, IG [1 ]
Ryvo, L [1 ]
Sarid, D [1 ]
Asna, N [1 ]
Inbar, MJ [1 ]
机构：
[1] Tel Aviv Med Ctr & Sch Med, IL-64239 Tel Aviv, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7567
引用
收藏
页码：726S / 726S
页数：1
相关论文
共 50 条
  • [31] Long-term clinical results of the combination of cisplatin (C), vinblastine (V), DTIC (D) and interferon-alfa (I) with or without tamoxifen (T) for metastatic melanoma.
    Sanguino, A. M.
    Bedikian, A. Y.
    Legha, S. S.
    Detry, M. A.
    Papadopoulos, N. E.
    Hwu, P.
    Hwu, W.
    Kim, K. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 462S - 462S
  • [32] Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b
    Rosenberg, SA
    Yang, JC
    Schwartzentruber, DJ
    Hwu, P
    Marincola, FM
    Topalian, SL
    Seipp, CA
    Einhorn, JH
    White, DE
    Steinberg, SM
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) : 968 - 975
  • [33] High-dose interleukin-2 in patients with metastatic melanoma whose disease progressed after biochemotherapy
    Buzaid, Antonio Carlos
    Schmerling, Rafael Aron
    Vieira Guedes, Rodrigo Antonio
    de Freitas, Daniela
    William, William Nassib, Jr.
    MELANOMA RESEARCH, 2011, 21 (04) : 370 - 375
  • [34] Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: A randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group
    Keilholz, U
    Punt, CJA
    Gore, M
    Kruit, W
    Patel, P
    Lienard, D
    Thomas, J
    Proebstle, TM
    Schmittel, A
    Schadendorf, D
    Velu, T
    Negrier, S
    Kleeberg, U
    Lehman, F
    Suciu, S
    Eggermont, AMM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (27) : 6747 - 6755
  • [35] Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma
    Guida, M
    Latorre, A
    Mastria, A
    DeLena, M
    EUROPEAN JOURNAL OF CANCER, 1996, 32A (04) : 730 - 733
  • [36] SEQUENTIAL DACARBAZINE CISPLATIN AND INTERLEUKIN-2 IN METASTATIC MELANOMA - IMMUNOLOGICAL EFFECTS OF THERAPY
    REDMAN, BG
    FLAHERTY, L
    CHOU, TH
    NAKEFF, A
    PILLOTE, K
    KAPLAN, J
    JOURNAL OF IMMUNOTHERAPY, 1991, 10 (02): : 147 - 151
  • [37] Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-α-2a in patients with metastatic melanoma
    Dorval, T
    Négrier, S
    Chevreau, C
    Avril, MF
    Baume, D
    Cupissol, D
    Oskam, R
    de Peuter, R
    Vinke, J
    Herrera, L
    Escudier, B
    CANCER, 1999, 85 (05) : 1060 - 1066
  • [38] Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy
    O'Day, SJ
    Boasberg, PD
    Piro, L
    Kristedja, TS
    Wang, HJ
    Martin, M
    Deck, R
    Ames, P
    Shinn, K
    Kim, H
    Fournier, P
    Gammon, G
    CLINICAL CANCER RESEARCH, 2002, 8 (09) : 2775 - 2781
  • [39] Combination therapy with interferon-gamma and interleukin-2 for the treatment of metastatic melanoma
    Kim, CJ
    Taubenberger, JK
    Simonis, TB
    White, DE
    Rosenberg, SA
    Marincola, FM
    JOURNAL OF IMMUNOTHERAPY, 1996, 19 (01) : 50 - 58
  • [40] BIOCHEMOTHERAPY WITH THYMOSIN-ALPHA-1, INTERLEUKIN-2 AND DACARBAZINE IN PATIENTS WITH METASTATIC MELANOMA - CLINICAL AND IMMUNOLOGICAL EFFECTS
    LOPEZ, M
    CARPANO, S
    CAVALIERE, R
    DILAURO, L
    AMEGLIO, F
    VITELLI, G
    FRASCA, AM
    VICI, P
    PIGNATTI, F
    ROSSELLI, M
    RASI, G
    GARACI, E
    ANNALS OF ONCOLOGY, 1994, 5 (08) : 741 - 746
12345